Preclinical contract research organization selection: model, conduct standard and contract

Selecting and scoping the work

1. Start from the question, and let it choose the model. Efficacy, mechanism and safety ask different things. Disease models vary enormously in how well they predict, and a provider's familiarity with one model is worth more than a slightly lower price on another. Ask what they run weekly, not what they can run.
2. Specify xenograft work properly or expect to repeat it. A xenograft study's result depends on the cell line and its authentication, the host strain and its immune status, the implantation site, the randomisation point by tumour volume and the endpoint definition. Any of these left to the provider's default is a variable you cannot reconstruct later.
3. Decide the conduct standard deliberately. Pivotal safety studies supporting a regulatory submission are conducted under good laboratory practice. Exploratory efficacy work generally is not, and conducting it to that standard adds cost without adding value. Deciding this late means repeating studies.
4. Read the animal welfare and quality position before the quotation. Institutional approval, facility accreditation, veterinary oversight and the humane endpoints in the protocol are documents, not assurances. They will be asked for later by a reviewer or a regulator.
5. Settle data, samples and intellectual property in the contract. Who owns the raw data, who holds the residual samples and for how long, what happens to a derived model or cell line, and who may publish. These are negotiable at contract and effectively fixed afterwards.

Study design questions worth settling before the quotation

Group sizes justified by a power calculation, randomisation and blinding where the endpoint is subjective, and a pre-specified analysis. These cost nothing to specify and are what makes the difference between a result and an anecdote.

Agree what happens to animals removed from study and how those are handled in the analysis. Exclusions decided after the fact are the single most common reason a striking preclinical result does not replicate.

Managing preclinical services once the study is running

Ask for interim data at agreed points rather than a report at the end. A study drifting off protocol is recoverable in week two and not in week ten, and providers generally welcome the contact.

Name one person on each side with authority to make a protocol decision. Studies delayed by a question nobody was empowered to answer are a recurring and entirely avoidable cost.

Reading the report

The report should carry the protocol and its amendments, the raw data or a clear route to it, all deviations with their assessment, and the analysis as pre-specified. A report presenting only the favourable analysis is not a report you can build a programme on.

Request the data in analysable form. Reconstructing a dataset from tables in a document introduces errors and makes independent re-analysis effectively impossible.

What a humanised model costs, and why

The price is the immunodeficient host, the human cells engrafted into it, the time to engraftment, the confirmation that engraftment succeeded, and barrier housing for an animal with no immune system of its own. The animal is the smallest part of it.

Ask what confirmation is included and at what level, because an animal that did not engraft is a wasted study arm. Ask also about the donor: a model built from one donor's cells carries that donor's genetics.

PBMC mice or stem cell mice: two ways to put a human immune system in a mouse

Engrafting mature peripheral cells is fast and gives a functional human T cell compartment quickly, and those cells recognise the mouse as foreign, so the window before graft-versus-host disease limits the study. It suits short experiments on human T cell function.

Engrafting stem cells gives a longer-lived, more complete system that develops in the host, at the cost of months to engraftment and a T cell compartment educated on mouse tissue. The question decides which, and neither is a human immune system.

admet drug discovery, and the assays behind the acronym

admet drug discovery covers absorption, distribution, metabolism, excretion and toxicity, and in practice it is a panel: solubility and permeability, microsomal and hepatocyte stability, protein binding, transporter and cytochrome interactions, and early toxicity screens. The order matters more than the breadth, since a compound that fails permeability does not need the rest, which is what keeps a screening cascade cheap.

Common questions

How do I choose a preclinical contract research organization for my disease models?

On model experience first, quality systems second, price third. A provider running your model routinely will produce cleaner data and spot a problem sooner than one running it for the first time at a lower rate.

Does every preclinical study need GLP?

No. Good laboratory practice applies to the safety studies supporting a submission. Exploratory efficacy and mechanism work is usually not conducted under it, and conducting it there adds cost without improving the science.

What should a xenograft study protocol fix in advance?

Cell line identity and authentication, host strain, implantation site and cell number, the tumour volume at which animals are randomised, the measurement schedule, the humane endpoint and the statistical plan. Each one changes the result.

Who owns the data from contract research organization services?

Whatever the contract says. Assume nothing: raw data ownership, residual sample custody, the right to publish and the ownership of anything derived are separate clauses and defaults differ between providers.

Which humanised model should I use?

Mature peripheral cells for short studies of human T cell function, accepting the graft-versus-host window. Stem cells for a longer-lived, more complete system, accepting months to engraftment and T cells educated on mouse tissue.

Browse by service class

• Compare Gene synthesis on advertised prices